Literature DB >> 1281207

RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.

A Rot1, M Krieger, T Brunner, S C Bischoff, T J Schall, C A Dahinden.   

Abstract

The cellular infiltrates of certain inflammatory processes found in parasitic infection or in allergic diseases consist predominantly of eosinophilic granulocytes, often in association with activated T cells. This suggests the existence of chemotactic agonists specific for eosinophils and lymphocyte subsets devoid of neutrophil-activating properties. We therefore examined four members of the intercrine/chemokine superfamily of cytokines (monocyte chemotactic peptide 1 [MCP-1], RANTES, macrophage inflammatory protein 1 alpha [MIP-1 alpha], and MIP-1 beta), which do not activate neutrophils, for their ability to affect different eosinophil effector functions. RANTES strongly attracted normal human eosinophils by a chemotactic rather than a chemokinetic mechanism with a similar efficacy as the most potent chemotactic myeloid cell agonist, C5a. MIP-1 alpha also induced eosinophil migration, however, with lower efficacy. RANTES and MIP-1 alpha induced eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in contrast to other chemotactic agonists such as C5a and formyl-methionyl-leucyl-phenylalanine (FMLP). RANTES, but not MIP-1 alpha, induced a biphasic chemiluminescence response, however, of lower magnitude than C5a. RANTES and MIP-1 alpha both promoted identical transient changes in intracellular free calcium concentration ([Ca2+]i), with kinetics similar to those induced by chemotactic peptides known to interact with G protein-coupled receptors. No cross-desensitization towards other peptide agonists (e.g., C5a, IL-8, FMLP) was observed, suggesting the presence of specific receptors. Despite its weaker eosinophil-activating properties, MIP-1 alpha was at least 10 times more potent on a molar basis than RANTES at inducing [Ca2+]i changes. Interestingly, RANTES deactivated the MIP-1 alpha-induced [Ca2+]i changes, while the RANTES response was preserved after MIP-1 alpha stimulation. MCP-1, a potent monocyte chemoattractant and basophil agonist, as well as MIP-1 beta, a peptide with pronounced homology to MIP-1 alpha, did not activate the eosinophil functions tested. Our results indicate that RANTES and MIP-1 alpha are crucial mediators of inflammatory processes in which eosinophils predominate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281207      PMCID: PMC2119467          DOI: 10.1084/jem.176.6.1489

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Leukocyte specificity and binding of human neutrophil attractant/activation protein-1.

Authors:  E J Leonard; A Skeel; T Yoshimura; K Noer; S Kutvirt; D Van Epps
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

Review 2.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

3.  Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils.

Authors:  P Kernen; M P Wymann; V von Tscharner; D A Deranleau; P C Tai; C J Spry; C A Dahinden; M Baggiolini
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes.

Authors:  T Yoshimura; E J Leonard
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

Review 5.  Human monocyte chemoattractant protein-1 (MCP-1).

Authors:  E J Leonard; T Yoshimura
Journal:  Immunol Today       Date:  1990-03

6.  Chemiluminescence detection of H2O2 produced by human neutrophils during the respiratory burst.

Authors:  M P Wymann; V von Tscharner; D A Deranleau; M Baggiolini
Journal:  Anal Biochem       Date:  1987-09       Impact factor: 3.365

7.  The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes.

Authors:  C G Larsen; A O Anderson; E Appella; J J Oppenheim; K Matsushima
Journal:  Science       Date:  1989-03-17       Impact factor: 47.728

8.  A novel cleavage product of beta-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils.

Authors:  A Walz; M Baggiolini
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

9.  The neutrophil-activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3-primed basophils.

Authors:  C A Dahinden; Y Kurimoto; A L De Weck; I Lindley; B Dewald; M Baggiolini
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Neutrophil-activating properties of the melanoma growth-stimulatory activity.

Authors:  B Moser; I Clark-Lewis; R Zwahlen; M Baggiolini
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  117 in total

Review 1.  Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.

Authors:  M Vukmanovic-Stejic; M J Thomas; A Noble; D M Kemeny
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

3.  High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.

Authors:  M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

4.  Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated Platelets.

Authors:  Susanne M Picker; Alexander Steisel; Birgit S Gathof
Journal:  Transfus Med Hemother       Date:  2009-03-04       Impact factor: 3.747

5.  Murine astrocytes express a functional chemokine receptor.

Authors:  S Tanabe; M Heesen; M A Berman; M B Fischer; I Yoshizawa; Y Luo; M E Dorf
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

6.  An In Vitro Investigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering.

Authors:  Jagoda M Jalowiec; Matteo D'Este; Jennifer Jane Bara; Jessica Denom; Ursula Menzel; Mauro Alini; Sophie Verrier; Marietta Herrmann
Journal:  Tissue Eng Part C Methods       Date:  2015-12-01       Impact factor: 3.056

7.  Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin.

Authors:  M M Teixeira; T N Wells; N W Lukacs; A E Proudfoot; S L Kunkel; T J Williams; P G Hellewell
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

8.  ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo.

Authors:  Patty J Lee; Xuchen Zhang; Peiying Shan; Bing Ma; Chun Geun Lee; Robert J Homer; Zhou Zhu; Mercedes Rincon; Brooke T Mossman; Jack A Elias
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

Review 9.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

10.  The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.

Authors:  Silvia Alvarez-Diaz; Christopher P Dillon; Najoua Lalaoui; Maria C Tanzer; Diego A Rodriguez; Ann Lin; Marion Lebois; Razq Hakem; Emma C Josefsson; Lorraine A O'Reilly; John Silke; Warren S Alexander; Douglas R Green; Andreas Strasser
Journal:  Immunity       Date:  2016-08-11       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.